A Huntington’s Breakthrough Hits a Very Real Wall
A late-stage trial for gene therapy AMT-130 showed it slowed Huntington’s disease progression by about 75%. But delivering it requires major brain surgery, and the FDA now has questions about the study’s design, clouding its approval path.